Many at-risk Americans either do not know about PrEP or don't have access. Here's why raising awareness is key to ending the ...

Tamar Braxton has announced a new brand partnership with Gilead Sciences. The music veteran will help educate and raise ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

Long-acting injectable PrEP may improve access, protection and adherence, especially for young people and pregnant women, according to Hasina Subedar, a senior technical advisor at South Africa’s ...

For some people, HIV feels like something that happens to “other people.” It’s a distant issue — something for a different ...

A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) among Black women.

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

"By improving awareness, access and trust in one of the most effective tools we have to prevent HIV," says the government's ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

By expanding access to PrEP through women's health hubs and NHS services, we're taking a vital step toward tackling inequality and protecting more people from acquiring HIV." ...

Yeztugo (lenacapavir) is now the first and only HIV prevention option approved by the U.S. FDA that offers protection for six months. Yeztugo received FDA approval under Priority Review.